These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 37382966)

  • 21. Phase separation is required for PML nuclear body biogenesis and function.
    Wu W; Tan Y; Yin H; Jiang M; Jiang Y; Ma X; Yin T; Li Y; Zhang H; Cai X; Meng G
    FASEB J; 2023 Jun; 37(6):e22986. PubMed ID: 37219517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SUMOylation regulates the number and size of promyelocytic leukemia-nuclear bodies (PML-NBs) and arsenic perturbs SUMO dynamics on PML by insolubilizing PML in THP-1 cells.
    Hirano S; Udagawa O
    Arch Toxicol; 2022 Feb; 96(2):545-558. PubMed ID: 35001170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PML nuclear bodies and apoptosis.
    Takahashi Y; Lallemand-Breitenbach V; Zhu J; de Thé H
    Oncogene; 2004 Apr; 23(16):2819-24. PubMed ID: 15077145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress.
    Dellaire G; Bazett-Jones DP
    Bioessays; 2004 Sep; 26(9):963-77. PubMed ID: 15351967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PML nuclear bodies: regulation, function and therapeutic perspectives.
    Sahin U; Lallemand-Breitenbach V; de Thé H
    J Pathol; 2014 Nov; 234(3):289-91. PubMed ID: 25138686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TGF-β induces PML SUMOylation, degradation and PML nuclear body disruption.
    El-Asmi F; El-Mchichi B; Maroui MA; Dianoux L; Chelbi-Alix MK
    Cytokine; 2019 Aug; 120():264-272. PubMed ID: 31153006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CACUL1/CAC1 attenuates p53 activity through PML post-translational modification.
    Fukuda T; Kigoshi-Tansho Y; Naganuma T; Kazaana A; Okajima T; Tsuruta F; Chiba T
    Biochem Biophys Res Commun; 2017 Jan; 482(4):863-869. PubMed ID: 27889610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the Prevalence and Roles of Proteins Undergoing Liquid-Liquid Phase Separation in the Biogenesis of PML-Bodies.
    Silonov SA; Mokin YI; Nedelyaev EM; Smirnov EY; Kuznetsova IM; Turoverov KK; Uversky VN; Fonin AV
    Biomolecules; 2023 Dec; 13(12):. PubMed ID: 38136675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress.
    Han Y; Huang C; Sun X; Xiang B; Wang M; Yeh ET; Chen Y; Li H; Shi G; Cang H; Sun Y; Wang J; Wang W; Gao F; Yi J
    J Biol Chem; 2010 Apr; 285(17):12906-15. PubMed ID: 20181954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The function, regulation and therapeutic implications of the tumor suppressor protein, PML.
    Guan D; Kao HY
    Cell Biosci; 2015; 5():60. PubMed ID: 26539288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.
    Meinecke I; Cinski A; Baier A; Peters MA; Dankbar B; Wille A; Drynda A; Mendoza H; Gay RE; Hay RT; Ink B; Gay S; Pap T
    Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5073-8. PubMed ID: 17360386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SUMO Modification of Hepatitis B Virus Core Mediates Nuclear Entry, Promyelocytic Leukemia Nuclear Body Association, and Efficient Formation of Covalently Closed Circular DNA.
    Hofmann S; Plank V; Groitl P; Skvorc N; Hofmann K; Luther J; Ko C; Zimmerman P; Bruss V; Stadler D; Carpentier A; Rezk S; Nassal M; Protzer U; Schreiner S
    Microbiol Spectr; 2023 Jun; 11(3):e0044623. PubMed ID: 37199632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells.
    Tessier S; Ferhi O; Geoffroy MC; González-Prieto R; Canat A; Quentin S; Pla M; Niwa-Kawakita M; Bercier P; Rérolle D; Tirard M; Therizols P; Fabre E; Vertegaal ACO; de Thé H; Lallemand-Breitenbach V
    Nat Commun; 2022 Sep; 13(1):5726. PubMed ID: 36175410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Swine Promyelocytic Leukemia Isoform II Inhibits Pseudorabies Virus Infection by Suppressing Viral Gene Transcription in Promyelocytic Leukemia Nuclear Bodies.
    Yu C; Xu A; Lang Y; Qin C; Wang M; Yuan X; Sun S; Feng W; Gao C; Chen J; Zhang R; Tang J
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promyelocytic Leukemia Protein (PML) Requirement for Interferon-induced Global Cellular SUMOylation.
    Maroui MA; Maarifi G; McManus FP; Lamoliatte F; Thibault P; Chelbi-Alix MK
    Mol Cell Proteomics; 2018 Jun; 17(6):1196-1208. PubMed ID: 29535160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NS5 Sumoylation Directs Nuclear Responses That Permit Zika Virus To Persistently Infect Human Brain Microvascular Endothelial Cells.
    Conde JN; Schutt WR; Mladinich M; Sohn SY; Hearing P; Mackow ER
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of promyelocytic leukemia protein in host antiviral defense.
    Geoffroy MC; Chelbi-Alix MK
    J Interferon Cytokine Res; 2011 Jan; 31(1):145-58. PubMed ID: 21198351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies.
    Roussigne M; Cayrol C; Clouaire T; Amalric F; Girard JP
    Oncogene; 2003 Apr; 22(16):2432-42. PubMed ID: 12717420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human Regulatory Protein Ki-1/57 Is a Target of SUMOylation and Affects PML Nuclear Body Formation.
    Saito Â; Souza EE; Costa FC; Meirelles GV; Gonçalves KA; Santos MT; Bressan GC; McComb ME; Costello CE; Whelan SA; Kobarg J
    J Proteome Res; 2017 Sep; 16(9):3147-3157. PubMed ID: 28695742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
    Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
    Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.